GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Apnea overview

Sleep apnea is a disorder that causes you to stop breathing while asleep. When a person is sleeping, throat and tongue muscles relax, and that soft tissue can block your airway. There are three types of sleep apnea central sleep apnea, obstructive sleep apnea, and complex sleep apnea. Symptoms of sleep apnea include loud snoring, episodes where you stop breathing during sleep, gasping for air. The most common cause of obstructive sleep apnea in adults is excess weight and obesity. Central sleep apnea happens when brain doesn’t send the signals needed to breathe. A breathing device, such as a continuous positive airway pressure (CPAP) machine, is the most common treatment for sleep apnea.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.